Clinical Trials Directory

Trials / Completed

CompletedNCT03471039

PACAP27 Headache Properties in Migraine Without Aura Patients

Pituitary Adenylate Cyclase-activating Polypeptide (PACAP27) Headache Properties in Migraine Without Aura Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Danish Headache Center · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a signaling molecule, localized in sensory and parasympathetic perivascular nerves fibres. PACAP exists i to functional iso-forms Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and PACAP27.

Conditions

Interventions

TypeNameDescription
DRUGPACAP27Infusion of PACAP27 over 20 minutes.
DRUGSalineInfusion of Saline over 20 minutes.

Timeline

Start date
2017-08-30
Primary completion
2018-08-30
Completion
2018-09-30
First posted
2018-03-20
Last updated
2019-01-24

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03471039. Inclusion in this directory is not an endorsement.

PACAP27 Headache Properties in Migraine Without Aura Patients (NCT03471039) · Clinical Trials Directory